Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00624858 · ClinicalTrials.gov registry record · Phase 2
A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression
A Phase 2 study of Depression, sponsored by Orexigen Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00624858 is a Phase 2 study of Depression that has completed, run by Orexigen Therapeutics. The registered enrollment target is 25 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00624858, a Phase 2 study of Depression, has completed, sponsored by Orexigen Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of major depression in overweight or obese subjects.
Conditions Studied
Interventions
- DRUG naltrexone SR 32 mg/ bupropion SR 360 mg daily
Study Locations (1)
Ohio
- Lindner Center of HOPE - Mason
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00624858
The ClinicalTrials.gov registry entry for NCT00624858 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The listed sponsor is Orexigen Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which naltrexone SR 32 mg/ bupropion SR 360 mg daily is the first listed.
NCT00624858 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00624858 about?
NCT00624858 is a clinical study titled "A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression". The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of major depression in overweight or obese subjects.
What is the current status of trial NCT00624858?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2008-01. Estimated completion is 2009-07.
What conditions does trial NCT00624858 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00624858?
The interventions under investigation include: naltrexone SR 32 mg/ bupropion SR 360 mg daily (DRUG).
Who is sponsoring clinical trial NCT00624858?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00624858 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.